Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
Wishart
Gordon C
GC
Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. gordon.wishart@addenbrookes.nhs.uk
Chetty
Udi
U
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001940:Breast / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D004164:Diphosphonates / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D000077289:Letrozole; D008403:Mass Screening; D008408:Mastectomy / Q000379:methods / Q000706:statistics & numerical data*; D009570:Nitriles / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage; D000077211:Zoledronic Acid
D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077211:Zoledronic Acid; D000077289:Letrozole